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Abstract: Some of the most commonly prescribed medications are those for cardiovascular 
maladies. The beneficial effects of these medications have been well documented. However, 
there can be substantial variation in response to these medications among patients, which may 
be due to genetic variation. For this reason pharmacogenomic studies are emerging across all 
aspects of cardiovascular medicine. The goal of pharmacogenomics is to tailor treatment to an 
individual’s genetic makeup in order to improve the benefit-to-risk ratio. This review examines 
the potential pharmacogenomic parameters which may lead to a future of personalized medicine. 
For example, it has been found that patients with CYP2C9 and VKORC1 gene variations have 
a different response to warfarin. Other studies looking at β-blockers, ACE inhibitors, ARBs, 
diuretics and statins have shown some results linking genetic variations to pharmacologic 
response. However these studies have not impacted clinical use yet, unlike warfarin findings, 
as the small retrospective studies need to be followed up by larger prospective studies for 
definitive results.
Keywords: cardiovascular, pharmacogenomics, genetics, cardiovascular medicine, personalized 
medicine, polymorphism
Introduction
Cardiovascular disease (CVD) is the number one cause of death, even with today’s 
technological advancements. According to the American Heart Association, 
approximately 80 million people (one out of three) have one or more forms of CVD.1 
This places a major burden to improve the treatment of CVD. Doctors commonly use 
trial and error in discovering what medicine will work for each patient; but what if 
doctors were able to prescribe medications based on the specific genetic make up of a 
patient, knowing beforehand which medicine will work best for this patient and how 
this patient would respond.2,3 There are many factors that can contribute to how a patient 
responds to a certain drug such as age, sex, body weight, nutrition, organ function, 
infections, concomitant medications, and genetic factors.4 There has been a recent shift 
from looking at single genes (genetics) to focusing on the functions and interactions 
of the whole genome.5 One major focus of today’s pharmacogenomic research is in 
the field of cardiovascular medicine.6 Currently there are many studies related to this 
topic in cardiovascular medicine, generating some statistically significant findings that 
are and will change the way doctors treat patients on an individual level. In this review 
we will focus on pharmacogenomics in: warfarin, β-blockers, angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), diuretics, and 
statins. Table 1 briefly outlines the polymorphisms reviewed.Pharmacogenomics and Personalized Medicine 2009:2 60
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Pharmacogenomics
Pharmacogenomics is the study of how a patient’s genes 
could affect their response to a drug;2 it is a way to 
personalize medicine and prescribe the optimal drug at the 
most advantageous dose for that patient, instead of a one 
drug fits all or trial and error theme. In the future doctors 
could predict who would respond to a drug and who would 
experience adverse reactions.7 Even with our advances in 
medicine, not every patient will have a full response to every 
drug.8 Another major problem with current cardiovascular 
medications is the adverse drug reactions, which are a 
major cause of hospitalizations in the United States today. 
Pharmacogenomics could help identify which patients would 
not benefit from a drug and avoid adverse effects potentially 
leading to toxicity and death.7 Overall, pharmacogenomics 
could lead to the selection of the most effective, safe medicine 
at accurate dosing regimens, which would potentially decrease 
health care costs dramatically. Reducing hospitalizations 
due to adverse events, the number of failed drug attempts and 
the number of medications a patient may need to take to find 
a effective regimen are all reasons pharmacogenomics would 
not only be beneficial to patients but be cost effective.6
Genotyping technologies have shown positive advancements 
in comprehending the human genome and how genetic variations 
can have substantial effects.7 The exact reason for variability in 
drug response is not clearly known, however there is evidence 
that genetics are partially responsible at least.9 Researchers have 
focused on single-nucleotide polymorphisms (SNPs) and DNA 
copy number variants (CNVs). Pharmacogenomic studies are 
attempting to link SNPs or CNVs to the expression of a target 
gene and eventually to how individual patients would respond 
to a medication.7 Using a DNA microarray, or a DNA chip, 
one can determine which genes are expressed. One problem 
is that we know that drugs respond to genetic and nongenetic 
factors, but we are not sure how much each factor effects the 
variation in drug response.7 One form of pharmacogenomics 
that is currently being used are the cytochrome P450 (CYP) 
enzymes. CYP enzymes are responsible for metabolizing many 
classes of medications, including cardiovascular medications. 
DNA variations in genes that code for these CYP enzymes 
could then cause either an overactive enzyme or an inactive 
form. If a patient had a DNA variation causing an inactive 
enzyme the drug could build up in the body, possibly leading 
to serious toxicity.4 The inclusion of pharmacogenetic data such 
as CYP polymorphisms is starting to be seen in drug package 
inserts. Specifically, the package insert for warfarin provides 
doctors with genomic information regarding drug dosing and 
how people’s responses may vary.10
Pharmacogenomics with warfarin
Some of the most promising pharmacogenomic data right 
now is with the anticoagulant warfarin. Warfarin is the 
Table 1 Polymorphisms reviewed for their association in drug response variability with cardiovascular medications
Drug or drug class Gene Polymorphism Functional role References
warfarin CYP2C9 CYP2C9 2* and 3* alleles enzymatic activity 3, 8, 10–12, 14
vKOrC1 -1639G  A and  
-1173C  T
required to activate clotting 
factors
3, 8, 10, 11, 
13, 14
Beta blockers ADrB1 Ser49Gly Mediate the effects 
of epinephrine and 
nor-epinephrine
8, 15, 16
Arg389Gly 8, 9, 15–17
ADrB2 Gly16Arg 8, 15, 16
Gln27Glu 8, 15, 16
ACe inhibitors and ArBs ACe i/D involved in converting 
angiotensin i to  
angiogensin ii
8, 16, 18–20
AGT Met235Thr 16, 18, 19
AT1r A1166C 8, 16, 18, 19
Diuretics α-adducin Gly460Trp renal tubular sodium 
re-absorption
8, 20, 22, 23
NPPA T2238C Controls electrolyte 
homeostasis
24
Statins MDr1/ABC ABCG5 and  
ABCG8
Cholesterol transport across 
the plasma membrane
25, 29
HMGCr SNP 12 and 29 on 
chromosome 5
Cholesterol synthesis 25, 27, 30
LDLr rs688 receptor for plasma LDL 25, 31
APOe ε2, ε3, and ε4 Major binding protein for 
vLDL/iDL cholesterol
8, 25, 27
Abbreviations:   ACe, angiotensin-converting enzyme;   ArB, angiotensin receptor blockers; LDL, low-density lipoprotein; LDLr, LDL receptor; vLDL, very LDL.Pharmacogenomics and Personalized Medicine 2009:2 61
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most commonly prescribed anticoagulant for the prevention 
and treatment of thromboembolic events.11 Unfortunately, 
warfarin has a narrow therapeutic index, which means 
that even a small change in the dose could lead to adverse 
affects. Patients that take drugs with a narrow therapeutic 
index require constant monitoring to insure a safe level 
and uniform results. If the dose of warfarin is too high, 
significant bleeding events may occur. On the other 
hand, if the dosing is too low, thromboembolic events 
will not be prevented as intended. Prothrombin time and 
international normalized ratio (INR) are used to moni-
tor the anticoagulation status of warfarin.12 Warfarin is 
metabolized via the hepatic cytochrome P450 enzyme, 
specifically CYP2C9. Drugs either inhibiting or enhancing 
the CYP2C9 can have detrimental effects on warfarin 
since it has a narrow therapeutic index. Any variation in 
the CYP2C9 enzyme can also cause some patients to have 
a slower metabolism of warfarin, meaning the drug will 
stay in the body for a longer period of time, thus putting 
the patient at an increased risk of bleeding.12 Recently 
a possible pharmacodynamic mechanism of warfarin 
resistance has been revealed with the warfarin target gene. 
This gene encodes vitamin K epoxide reductase complex 1 
(VKORC1), which recycles reduced vitamin K. The figure 
below shows warfarin’s CYP metabolism and the role of 
vitamin K reductase. Since vitamin K reductase is encoded 
by VKORC1 warfarin’s anticoagulant effect will also be 
affected by polymorphisms in this gene.13 Prior to pharma-
cogenomic studies, warfarin-dosing regimens were based 
on age, sex, weight and co-medication. With the advent of 
pharmacogenomics, variations in CYP2C9 and VKORC1 
enzymes should also be considered.14
The first main gene studied for its warfarin dose-related 
effects is the CYP2C9 gene. Studies show that there are two 
main variant alleles of CYP2C9, the *2 allele and the *3 
allele.11 These alleles have been shown to cause reductions 
in enzymatic activity by approximately 30% and 80% 
respectively, thus increasing the chance of bleeding.12 There 
have been many studies on the CYP2C9 variant alleles 
conferring similar results. The mean warfarin dose in the 
*3 allele was significantly lower than the *2 allele and the 
wildtype allele (*1/*1). The *2 allele warfarin dose was 
also significantly lower compared to wildtype. These find-
ings suggest that maybe there is a gene-dose relationship.14 
Variant alleles were also associated with an increased time 
to reach stable dosing as compared to wildtype12 and an 
increased risk to have above range INR’s (INR  3.2).11 
Lastly, there was an increased risk of bleeding in patients 
with the variant alleles when compared to the wild type. 
Patients with the *3 allele had a higher risk of bleeds (above 
range INR’s) and took a longer time to reach a stable dosing 
regimen compared to those with the *2 allele, but both of 
these variants had a higher risk of bleeds than the wildtype. 
Optimistically, with the use of genotype-guided dosing, we 
can reduce the risk of above range INR’s, bleeds, and time 
to reach stable dosing.12
VKORC1 codes for vitamin K reductase. Vitamin K 
reductase is responsible for recycling oxidized vitamin K back 
to its reduced form after it has carboxylated several coagula-
tion factors and proteins. Factors II, VII, IX, and X as well as 
proteins C, S, and Z are dependent on these steps to become 
functional (Figure 1). Certain variations of the VKORC1 gene 
will result in reduced activity of the enzyme, which further 
reduces the activity of vitamin K-dependent clotting factors, 
thus leading to bleeds.13 There have been several studies with 
numerous SNP’s, all showing similar outcomes. Specifically 
studied were polymorphisms at position -1639 and -1173. For 
these positions, carriers of A and T required significantly lower 
doses of warfarin compared to G and C carriers, respectively. 
For both of these positions, there was a significant risk of 
increased INR’s for variant alleles.11,14 There have also been 
several studies looking at group A and B haplotypes. Haplo-
types containing a B variant require significantly higher mean 
warfarin daily doses compared to group A. Although different 
polymorphisms have been studied, the VKORC1 genotype 
seems to be the most important genetic factor in establishing 
inconsistencies in warfarin doses.13
These two pharmacogenomic advancements have 
recently begun to be taken into consideration when pre-
scribing anticoagulant regimens. Recently, there have been 
changes to the warfarin package insert to include information 
on CYP2C9 and VKORC1 gene variations, recommending 
considering lower doses for patients with genetic variations 
in these genes; as these variations may put the patient at risk 
for adverse events.10 These changes do not tell physicians they 
need to change their dosing regimens. Since this is a fairly 
new topic, this information was added to make physicians 
aware of the potential variations in dose response in these 
patients. Currently there are genetic tests available for 
CYP2C9 and VKORC1 genotyping.8 Unfortunately, since 
these tests are still relatively new, they are not being used 
as much as they should. This could lead to at risk patients 
to develop adverse affects and additional avoidable costs.3 
Since warfarin is very commonly prescribed and has a narrow 
therapeutic window, many more studies will arise in the near 
future. Hopefully with larger prospective studies showing Pharmacogenomics and Personalized Medicine 2009:2 62
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conclusive evidence, warfarin will have genotype-guided 
dosing regimens.
Pharmacogenomics  
with beta-blockers
β-blockers have shown to be promising in the treatment 
of hypertension, heart failure (HF) and myocardial 
infarction.8 β-blockers block the effects of norepineph-
rine and epinephrine, thereby slowing nerve impulses to 
the heart and thus decreasing the workload of the heart. 
As their name states, β-blockers antagonize the β1 and β2 
adrenergic receptors (ADRB1 and ADRB2, respectively).15 
Currently there are several classes of β-blockers that work 
differently; depending on whether they are selective, 
nonselective and if they block just β receptors or β and 
α receptors. ADRB1 polymorphisms have been studied 
and Ser49Gly and Arg389Gly have been shown to possibly 
effect receptor function.16 ADRB2 polymorphisms have 
also been looked at and studies show that Gly16Arg and 
Gln27Glu may affect receptor function.8 The main focus of 
pharmacogenomics with β-blockers is to determine if these 
polymorphisms could be a potential factor for the variable 
responses to this class of medications.15
The majority of the pharmacogenomic studies in this 
class of medications are on ADRB1 and its potential 
polymorphisms including Ser49Gly and Arg389Gly.16 
There has been a greater overall response to β-blockers 
for the 389Arg genotype as compared to the Gly genotype. 
The 389Arg genotype has been found to show significant 
improvements in left ventricular ejection fraction (LVEF) 
in response to β-blockers,9 larger reductions in heart rate 
and blood pressure8 and significant overall decrease in 
hospitalizations and mortality compared to the Gly389 
carriers.17 Therefore, patients with the 389Arg genotype 
treated with β-blockers showed overall better results 
when matched up to Gly389 carriers. If we look at the 
Ser49Gly polymorphism, Gly49 has been associated with 
greater reductions in end diastolic diameter compared to 
the 49Ser genotype. The 49Ser genotype has also been 
associated with an increase in heart rate and an overall 
increase in mortality as compared to Gly49 carriers treated 
with β-blockers.8
There have been several studies reviewing the ADRB2 
polymorphisms (Gly16Arg and Gin27Glu), but the results 
have not shown a large amount of conclusive evidence.16 
The 27Gin and 16Arg genotypes have been associated with 
Figure 1 warfarin is metabolized into r-warfarin and S-warfarin, which prevent coagulation by inhibiting vitamin K reductase.   vitamin K reductase recycles oxidized vitamin K 
back to its reduced form after it has carboxylated several coagulation factors and proteins.   These steps are necessary for factors ii, vii, iX, and X as well as proteins C, S, and 
Z to become functional. it has been found that the more potent S-warfarin is metabolized mainly via CYP2C9 and therefore polymorphisms in CYP2C9 could account for 
inter-patient variability in warfarin response.
CYP2C9 CYP2C9
CYP1A1 CYP1A1
CYP1A2 CYP1A2
CYP3A4 CYP3A4
Oxidized Vitamin K Oxidized Vitamin K Reduced Vitamin K Reduced Vitamin K
O O2 2
Hypofunctional Hypofunctional
F. II, VII, IX, X F. II, VII, IX, X
Proteins C, S, Z Proteins C, S, Z
Functional  Functional 
F. II, VII, IX, X F. II, VII, IX, X
Proteins C, S, Z Proteins C, S, Z
γ- -glutamyl  glutamyl 
carboxylase carboxylase
Vitamin K  Vitamin K 
Reductase Reductase
CO CO2 2
Calumenin
R-warfarin S-warfarin R-warfarin S-warfarin
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overall increases in mortality in patients receiving β-blockers 
as compared to the Glu and Gly carriers. Unfortunately there 
hasn’t been a great deal of promising information in this 
set of polymorphisms, but this may be helpful for future 
pharmacogenomic research.8
Overall, many studies have shown favorable outcomes in 
patients with the ADRB1 Arg389 polymorphism, however 
there have also been studies showing inconclusive results.8,17 
More pharmacogenomic research needs to be completed 
on both ADRB1 and ADRB2 in order to determine if these 
mutations truly affect β-blocker effectiveness. Another area 
of interest are the CYP2D6 enzymes which metabolize the 
majority of β-blockers; potential polymorphisms in this 
enzyme could affect the metabolism of β-blockers.16 Another 
concerning factor for future research is that there are several 
classes of β-blockers, which effect the receptors differently.16 
So before any general conclusions can be made, more drugs 
within each class must be studied. If future research shows 
significant beneficial effects, genotyping prior to starting 
β-blockers could be performed to see who would obtain the 
greatest benefit.
Pharmacogenomics with ACE 
inhibitors and ARBs
Both ACE inhibitors and ARBs are universally prescribed 
for the treatment of hypertension and other cardiovascular 
problems. Both of these classes of medications work by 
antagonizing the renin–angiotensin–aldosterone system 
(RAAS). ACE inhibitors work by blocking the conversion of 
angiotensin I to angiotensin II and ARBs work by blocking 
the stimulation of angiotensin II receptors (AT1R).18 Overall, 
both of these classes of medications are effective in reducing 
blood pressure; however, recent pharmacogenomic studies 
are assessing possible polymorphisms that may affect the 
end results for patients. There have been many studies 
looking at polymorphisms such as an insertion/deletion 
(I/D) polymorphism in the ACE gene, a polymorphism in the 
angiotensinogen (AGT) Met235Thr gene and some research 
with a polymorphism in the gene encoding AT1R.16,19 The 
main focus of these studies were to determine if these genetic 
mutations could in fact alter the response a patient may have 
to a specific drug in these particular therapeutic classes.
The ACE gene is an important place for a potential 
polymorphism because the ACE gene plays a major role in the 
RAAS. Currently the majority of these studies are focusing 
on insertion/deletion (I/D) polymorphisms in the ACE gene.8 
When it comes to assessing how this polymorphism could 
affect blood pressure, there have been conflicting results. 
Similar inconclusive results were seen in studies looking at 
coronary heart disease (CHD) risk for the different genes.16,20 
A six-year hazard rate showed no significant differences 
in CHD, stroke or mortality among any of the genotypes 
treated with ACE inhibitors.20 Studies did show that there 
were significantly more D/D genotypes than I/D or I/I in the 
black population.8 Studies have also looked at the affect of 
the I/D polymorphism with respect to ARBs, however no 
conclusive results were found.16 Overall, there have been a 
wide variety of studies showing inconclusive results with the 
I/D polymorphism in the ACE gene. Currently there is no 
definitive association between this gene and CHD risk and 
response to ACE or ARB treatment.
A second main focus is with the angiotensinogen 
(AGT) Met235Thr polymorphism.18 This became a 
focus of pharmacogenomic interest because AGT could 
potentially affect the mechanism of action of ACE 
inhibitors.16 Studies have shown that people with 235Thr 
alleles have higher circulating levels of angiotensin in their 
plasma than those with Met alleles. These studies also show 
that there may be an association between the 235Thr allele and 
increased blood pressure.16 Now studies are looking to see if 
the M or T alleles affect the response to ACE inhibitors, or are 
linked to stroke or myocardial infarction (MI) with conflicting 
results; therefore the contribution of this polymorphism 
to blood pressure response and any link to stroke or MI 
remains uncertain.16,18 Larger studies need to be completed 
to determine the exact role, if any, this polymorphism play 
in blood pressure response and stroke or MI.
Another polymorphism that has been looked at is the gene 
encoding AT1R, especially for possibly affecting the response 
to ARBs.8 The most common polymorphism of this gene is 
the A1166C. However, studies gave inconsistent results and 
currently there are no significant conclusions with regards 
to this polymorphoism.16
In conclusion, the current data available does not show that 
polymorphisms in the ACE, AGT or AT1R genes affect blood 
pressure response to ACE inhibitors or ARBs.16,18,20 There 
have been many studies in relation to these polymorphisms, 
nonetheless the majority have conflicting results and/or 
several limitations thus affecting the credibility of the results. 
Hopefully researchers will continue to study these genes, 
along with others, to find some conclusive evidence that could 
change the way physicians prescribe these medications.
Pharmacogenomics with diuretics
Diuretics play a major role in the treatment of hypertension. 
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Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure, the majority of the 
compelling indications requiring hypertensive treatment(s) 
have thiazide diuretics listed as a first-line choice.21 Diuretics 
are proven to be very effective in helping patients reach their 
blood pressure goal of 140/90 mmHg (130/80 mmHg 
for patients with diabetes or chronic kidney disease).21 
Unfortunately there can be significant variation in blood 
pressure responses to diuretics depending on the individual. 
Therefore, diuretics pose a good place for pharmacogenomic 
studies to figure out whether genetic polymorphisms are, 
at least partially, causing this inter-patient variability in 
responses.22 There have been several studies in regards to 
the adducin gene, which is a cytoskeletal protein consisting 
mainly of an α and β subunit.23 There are three human genes 
(ADD1, ADD2, and ADD3) which encode these subunits.22 
There has also been some research into the atrial natriuretic 
precursor A (NPPA) gene with regards to inter-patient 
responses with diuretics.24
The α-adducin gene (ADD1) has specifically been 
researched because of its association with thiazide diuretics 
in patients with hypertension. ADD1 is associated with 
renal tubular sodium reabsorption by sodium/potassium 
ATPase.23 Specifically, researchers have been looking at 
the SNP Gly460Trp in ADD1. This polymorphism has been 
associated with a form of salt-sensitive hypertension.8 Several 
studies confirmed that the 460Trp variant was associated 
with a greater reduction in blood pressure when treated with 
hydrochlorothiazide as compared to the wildtype.8,20 The 
460Trp variant, treated with a thiazide diuretic, was also 
associated with a significantly lower risk of MI and stroke. 
However diuretic therapy with the wildtype allele was not 
associated with the risk of MI or stroke.23 Unfortunately 
there have been other studies with contradicting findings, 
showing that there was no association between ADD1 and 
blood pressure lowering or CHD risk, specifically with 
chlorthalidone.8 There has also been some thought that 
ADD3 G/G homozygote could also cause hypertension, 
however more research is needed.22 Overall, these studies 
show that the ADD1 gene may potentially affect blood 
pressure responses to diuretics; however more conclusive 
studies need to be completed.
The NPPA gene has also been involved in pharmacoge-
nomic studies. The NPPA gene is necessary to derive the 
atrial natriuretic peptide (ANP). ANP acts as a diuretic by 
controlling electrolyte homeostasis and extracellular fluid 
volume.24 Keeping this in mind, a reduced ANP level could 
be associated with hypertension, while an increase in ANP 
could result in hypotension. The SNP NPPA T2238C has 
been the main focus of recent studies. For the T2238C variant, 
the C allele carriers were associated with lower CHD event 
rates as well as larger reductions in blood pressure com-
pared to the T alleles when treated with chlorthalidone vs 
amlodipine. The TT genotype was associated with a greater 
risk of MI, stroke and all-cause mortality when treated with 
chlorthalidone compared to amlodipine.24 This study showed 
promising data. However, there were several limitations so 
further pharmacogenomic studies on the NPPA gene need 
to be conducted.
Even though the ADD1 and NPPA polymorphisms 
showed some significant positive findings, pharmacoge-
nomic studies have yet to impact how physicians prescribe 
diuretics.22–24 There have been too many studies with con-
flicting evidence to be used at this time. Given the actions 
of adducin and the ANP gene, the ADD1 and NPPA poly-
morphisms seem to be excellent areas of cardiovascular 
pharmacogenomics.22,24 Overall, diuretics are safe and effec-
tive in treating hypertension and other complications like MI, 
stroke or heart failure so they will continue to be a mainstay 
in drug therapy. Hopefully, with further pharmacogenomic 
studies, diuretic adjustments can be made based on a patient’s 
specific genetic make up.
Pharmacogenomic with statins
HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme 
A) reductase inhibitors (statins) are a class of medications 
that lower cholesterol levels by decreasing cholesterol 
production in the liver.25 Statins are a first-line therapy for 
the prevention of coronary artery disease (CAD), which 
happens to be a major leading cause of death.26 Statins, as 
their drug name states, inhibit HMG-CoA reductase, which 
is the rate-limiting step in the biosynthesis of cholesterol. 
Inhibiting the biosynthesis of cholesterol reduces the 
secretion of apolipoprotein B (apoB) and upregulates 
the low-density lipoprotein (LDL) receptor activity, thus 
lowering cholesterol in plasma.25 Cholesterol and lipids 
can cause plaque build-up or atherosclerosis. Even though 
statins are proven to be beneficial in the majority of people, 
some people have varying responses to these medications.27 
At first, environmental and social influences were thought 
to cause this variation; however more recent investigations 
have focused on genetic variations, or polymorphisms, 
which could be causing this variation in drug response.28 
There have been approximately 30 genes studied in refer-
ence to this possible genetic contribution. Unfortunately not 
many of these studies have had follow up studies or similar Pharmacogenomics and Personalized Medicine 2009:2 65
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studies to compare the results to, therefore there are not many 
significant conclusive findings.25
One major factor potentially affecting statin responses is 
due to their metabolism via the cytochrome P450 system.8 
Lovastatin, simvastatin and atorvastatin are metabolized 
by CYP3A4, whereas CYP2C9 metabolizes fluvastatin. 
Lastly, pravastatin and rosuvastatin do not appear to be 
metabolized by the cytochrome P450 system. One could 
assume that CYP activity could cause a degree of variation 
in drug response and small studies have proven this. For 
example, lovastatin was significantly less effective in 
patients who expressed CYP3A5, compared to patients 
whom did not.25
P glycoprotein, also known as multidrug resistance-1 
(MDR1) or ATP-binding cassette transporter (ABC), have 
been found to affect drug disposition. Several polymorphisms 
in the MDR1 have been examined, but further, larger 
studies are needed. ABC subfamilies G5 and G8 have been 
studied (ABCG5 and ABCG8 respectively); specifically the 
ABCG8 D19H polymorphism was associated with a greater 
reduction in LDL when treated with atorvastatin.29 This 
polymorphism was also linked to a reduction in intestinal 
cholesterol absorption.25 HMG-CoA reductase (HMGCR) 
is the target for statin therapy, so genes encoding this have 
been the focus of several studies. One study showed that 
there was a significant association between SNP 12 and 29, 
Table 2 Pharmacogenomics and cardiovascular medicines
Polymorphisms affecting warfarin response
• CYP2C9 variant alleles, *2 and *3, are associated with:
°  Lower mean warfarin doses
°  increased risk of elevated iNrs leading to a increased risk of bleeds
• Polymorphisms in the vKOrC1 at position -1639 and -1173 require lower doses of warfarin
Polymorphisms affecting β-blocker response
• The ADrB1 Ser49Gly and Arg389Gly polymorphisms seem to positively impact the response to β-blockers including increasing LveF, reducing 
mortality and larger reductions in heart rate and blood pressure
°  However there remains inconclusive evidence preventing its clinical use
• Current information on the polymorphisms of ADRB2, Gly16Arg and Gln27Glu, are not sufficient enough to confirm a relation to dose response 
variation
Polymorphisms affecting ACE inhibitors or ARB response
• Current information on the I/D polymorphism associated with the ACE gene has shown conflicting results
• inconsistencies with the AGT Met235Thr polymorphism prevent its clinical use
• A small number of studies showed inconsistent results on the AT1r   A1166C polymorphism
Polymorphisms affecting diuretic response
• The 460Trp variant of the ADD1 Gly460Trp polymorphism may be associated with greater reductions in blood pressure and lower risk of Mi or 
stroke in patients treated with a thiazide diuretic
°  However, other studies have showed conflicting results
• The C allele of the NPPA T2238C polymorphism has been associated with lower CHD event rates and larger reductions in blood pressure when 
treated with a diuretic compared to the T allele
Polymorphisms affecting statin response
• The ABCG8 D19H polymorphism may be associated with greater reductions in LDL when treated with atorvastatin
• SNPs 12 and 29 of the HMGCr may be associated with smaller reductions in total cholesterol and LDL
• A SNP within the LDLr exon 12, rs688, may increase LDL in women
• APOe ε4 has the highest risk of CHD, while ε2 has the lowest risk of CHD and ε3 falls in between ε2 and ε4
• APOe ε2 and ε3 have greater reductions in LDL compared to ε4 when treated with a statin
Conclusion and future perspective
• Currently the only pharmacogenomic data that is affecting clinical use is the CYP2C9 and vKOrC1 data with warfarin
• All of the other aforementioned results need further larger prospective studies to build on the results gathered in order to obtain more conclusive 
resultsPharmacogenomics and Personalized Medicine 2009:2 66
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both found on chromosome 5, with reduced efficacy of 
pravastatin therapy. Individuals who were homozygous for 
the minor allele had a 22% and 19% smaller reduction in total 
cholesterol and LDL, respectively, compared to heterozygous 
carriers.30 LDL-receptor (LDLR) genes have been the focus 
of some pharmacogenomic studies because of their role in 
cholesterol binding and metabolism. A SNP within the LDLR 
exon 12, rs688, has been associated with an increase in LDL 
cholesterol in women.31 These results should become the 
basis of further studies to confirm or expand the results in 
order for these polymorphisms to be used clinically.25
The most extensively researched pharmacogenomic topic 
in regards to lipid-lowering therapy is with the apolioprotein 
E polymorphisms (APOE).8 There are three APOE isoforms: 
ε2, the wildtype ε3 and ε4.25,27 APOE has several roles in lipid 
metabolism; APOE binds to LDLR and mediates the uptake 
of chylomicron, very low-density lipoprotein (VLDL) and 
intermediate-density lipoprotein (IDL). This is why APOE 
polymorphisms can affect cholesterol and triglyceride 
levels.27 Several studies have shown that ε4 has the poorest 
response to statins, while ε2 has the strongest response in 
regards to LDL lowering. APOE ε2 is therefore more likely 
to reach LDL goals. APOE also acts as a protective agent 
against atherosclerosis. APOE ε4 carriers have the highest 
risk of CHD, ε2 has the lowest risk of CHD, and ε3 is in 
between.25,27
Even though there have been several pharmacogenomic 
studies in regards to lipid lowering effects, none are currently 
being used clinically. Larger studies need to be completed with 
specific statins and for each polymorphism. Like previously 
mentioned, not all of the statins are metabolized in the same 
way, therefore each statin could be affected by different 
genes.25 APOE and HMGCR seem to show the most promising 
data, however neither are currently being used clinically.27,30 
CYP450 enzymes have shown to be a specific area which 
could be useful, to help reduce the possibility for adverse 
effects including myalgia or rhabdomyolysis. Hopefully, in 
the future, pharmacogenomic studies will show clinically 
significant findings so they can be used to identify which statin 
would be best for each patient’s genetic makeup.
Conclusion
Cardiovascular medicine is perfect for pharmacogenomic 
studies. The main goal of pharmacogenomics is to reveal 
potential genetic alterations affecting the body’s response 
to a specific drug, leading to more personalized medicine. 
Pharmacogenomics can prove to be cost effective by 
hopefully decreasing the number of patients who experience 
adverse reactions. Researchers have been conducting 
pharmacogenomic studies on a variety of topics within 
cardiovascular medicine for years. Unfortunately the 
majorities of the studies have small sample sizes or reveal 
conflicting data. There needs to be larger, prospective 
controlled trials to build on the information already 
discovered. It would also be beneficial to have studies focusing 
on specific genes in relation to race, gender, and ethnicity, 
since some genes are more common in specific people. 
The good news for pharmacogenomics is that progresses in 
establishing potential genes affecting drug response have 
been found; the bad news is that the progression to use these 
findings in a clinical setting is taking a long time. As we have 
seen with warfarin, pharmacogenomics is not impossible. 
Currently there are genetic screening tests for CYP2C9 and 
VKORC1, which could affect warfarin dosing protocols. 
Changes were also made within warfarin’s package insert 
to include this information and the United States Food and 
Drug Administration “highlights the opportunity for health 
care providers to use genetic tests to improve their initial 
estimate of what is a reasonable warfarin dose for individual 
patients”.32 Perhaps many physicians are not yet following 
these recommendations as they are newer; but as awareness 
increases, more data is collected, and gene testing becomes 
more commonplace, VKORC1 and CYP2C9 will begin 
playing a larger role in warfarin dosing. Genomic screening 
and the adoption of personalized medicine can help save lives 
and dollars. Pharmacogenomics is on the horizon and may 
play an important role in the near future in the way physicians 
prescribe medicine; it is important to stay updated as we 
learn and discover the role pharmacogenomics plays, in all 
fields of medicine. Table 2 matches pharmacogenomics with 
cardiovascular medicines.
Future perspectives
Pharmacogenomics is a relatively new topic so the majority 
of the studies that have been conducted will provide 
starting points for future research. Hopefully the area of 
cardiovascular pharmacogenomics will continue to progress 
and lead to personalized medicine. Genetic screening tests 
will become part of standard warfarin dosing and potentially 
for other classes of medication. Within the next 5–10 years, 
more conclusive studies will hopefully unveil more specific 
polymorphisms that will change the way medications are 
prescribed.
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